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ABSTRACT: 
Introduction: Over the last decade there has been a number of guidelines published, 
aimed at improving the quality of reporting in published studies and reviews. In 
systematic reviews and meta-analyses this may be measured by their compliance with the 
PRISMA statement. 
Aims: Our aim is to assess the reporting quality of meta-analyses of randomized-
controlled trials exploring the efficacy and safety of the new anticoagulants versus 
warfarin in patients with atrial fibrillation, using the prisma checklist. 
Methods: A search was performed on MEDLINE and EMBASE databases. The meta-
analyses that we found were assessed with the prisma checklist, where each checklist 
item was scored with 1 point. The meta-analysis which received the most points was 
assessed as the best and most complete. 
Results: Five meta-analyses were pooled, which were all eligible according to their title 
and abstract. The assessment of these meta-analyses was performed with the prisma 
checklist and each checklist item was scored with 1 point. Compliance with the PRISMA 
statement was generally good. Meta-analyses No2 and 5 received the most points (24). 
Meta-analyses No1 and 4 received 23 points and meta-analysis No3 received two points 
(though its assessment was not complete as we were not able to have access to the full 
text).  
Conclusion: Meta-analyses No 2 and 5 are the most complete in terms of the prisma 
checklist assessment. However, there were not big differences in the scores that all meta-
analyses received. All scores were high. This indicates that the meta-analyses of 
randomized-controlled trials exploring the efficacy and safety of the new anticoagulants 
versus warfarin in patients with atrial fibrillation have a good reporting quality. 
 
 
 
INTRODUCTION: 
  Atrial fibrillation (AF) is the most common cardiac arrhythmia, with an overall 
prevalence of 5.5% that increases up to 17.8% in individuals 85 years of age. AF is 
a major risk factor for stroke, with a 30-day mortality rate of 24% in the absence of 
treatment. Vitamin K antagonists (VKAs) are highly effective for the prevention of 
stroke, mainly of ischemic origin, in patients with AF, resulting in a 64% risk reduction 
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compared with placebo and a 37% risk reduction compared with antiplatelet therapy. For 
this reason, VKAs are currently recommended in all AF patients at moderate to high risk 
for stroke or systemic embolism (SE). However, VKAs have significant limitations, 
particularly their unpredictable anticoagulant response and numerous food and drug 
interactions, mandating regular laboratory monitoring. These limitations make treatment 
with VKAs problematic for many patients; as a result, only about half of all potentially 
eligible AF patients are treated with VKAs. Over the last several years, novel oral 
anticoagulant drugs (NOACs), including direct thrombin inhibitors and factor Xa 
inhibitors, have been developed. These drugs have the potential to address some of the 
limitations of VKAs. These agents have fewer food and drug interactions and a more 
predictable anticoagulant effect, thus allowing fixed dosing without the need for 
laboratory monitoring. Furthermore, their shorter half-life may produce additional 
advantages, eg, if temporary interruption is required for a surgical procedure or in the 
case of an hemorrhagic complication.  
There are meta-analyses of randomized-controlled trials, which explore the efficacy and 
safety of the new anticoagulants versus warfarin in patients with atrial fibrillation. In 
order to assess the reporting quality of these meta-analyses, we are going to use the 
PRISMA statement. The aim of the PRISMA Statement is to help authors report a wide 
array of systematic reviews to assess the benefits and harms of a health care intervention. 
PRISMA focuses on ways in which authors can ensure the transparent and complete 
reporting of systematic reviews and meta-analyses. The 27 checklist items pertain to the 
content of a systematic review and meta-analysis, which include the title, abstract, 
methods, results, discussion and funding. 
 
Methods: 
We performed a search in the databases MEDLINE and EMBASE using the following  
search string :“atrial fibrillation AND warfarin AND (apixaban OR dabigatran OR 
edoxaban OR rivaroxaban OR ximelagatran) AND meta-analyses”. Five meta-analyses 
were pooled, which were all eligible according to their title and abstract. The quality of 
the reporting of the included meta-analyses was assessed according to the level of 
compliance with the PRISMA guidelines. These guidelines incorporate 27 items 
pertaining to each section of the review, including title, abstract, introduction, methods, 
results, discussion, conclusion, and funding. Each checklist item was scored with 1 point. 
The meta-analysis which received the most points was assessed as the best and most 
complete. 
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Results: 
Meta-analysis No1: 
Journal of Cardiovascular Pharmacology: 
October 2014 - Volume 64 - Issue 4 - p 368–374 
doi: 10.1097/FJC.0000000000000129 
Original Article 
Meta-analysis of Efficacy and Safety of the New Anticoagulants 
Versus Warfarin in Patients With Atrial Fibrillation 
 
Prisma Checklist: 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
Meta-analysis of Efficacy and Safety of the New Anticoagulants 
Versus Warfarin in Patients With Atrial Fibrillation 
 
368 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
Objective: To assess the efficacy and safety of the new oral 
anticoagulants versus warfarin in patients with atrial fibrillation by 
the meta-analyses performed for 5 studies ARISTOTLE, ENGAGE 
AF-TIMI 48, RE-LY, ROCKET-AF, and J-ROCKET. 
Methods: The events including primary efficacy endpoint (stroke 
and systemic embolism), ischemic stroke, hemorrhagic stroke, all-
cause mortality, and myocardial infarction were used for efficacy 
analysis and those including major bleeding, intracranial 
hemorrhage, and gastrointestinal bleeding were used for safety 
analysis. Instead of combining both doses to 1 meta-analysis, the 
high-dose groups of RE-LY (150 mg twice daily) and ENGAGE 
AF-TIMI 48 (60 mg twice daily) were combined with the single 
dose studies ARISTOTLE, ROCKET-AF, and J-ROCKET. A 
separate meta-analysis was done for the low-dose groups of RE-LY 
368 
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(110 mg twice daily) and ENGAGE AF-TIMI 48 (30 mg twice 
daily). 
Results: The high-dose regimen had better performance than low 
dose in efficacy. In addition, low-dose regimen demonstrated to 
significantly reduce the risk of hemorrhagic stroke, all-cause 
mortality, and intracranial hemorrhage. 
Conclusions: The new oral anticoagulants demonstrated promising 
alternatives to warfarin in prevention of stroke in patients with 
atrial fibrillation. 
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
Atrial fibrillation (AF) is a kind of arrhythmia, and there are about 
8 million patients with AF in China, 2.2 million in the United 
States and 4.5 million in Europe Union.1 It is known that AF is one 
of the independent risk factors for stroke and might increase its risk 
by up to 5-fold. The AF-related strokes are associated with higher 
risk of mortality and morbidity than non-AF strokes.2 For a half-
century, clinicians have prescribed aspirin or vitamin K antagonist 
(most commonly warfarin) for the patients with AF. Warfarin is 
always a preferred option to prevent stroke or systemic embolism 
events.3,4Although with the proven efficacy, its use is limited by 
some drawbacks including the narrow therapeutic window 
requiring frequent international normalized ratio (INR) monitoring 
and a high risk of bleeding.5,6 
 
 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
Therefore, as a result, some new oral anticoagulants (NOACs) 
inhibiting either activated factor X (factor Xa) or thrombin have 
been developed to provide a more promising option.7,8 The 4 large 
phase III randomized controlled trials (RCTs) RE-LY (Dabigatran 
randomized evaluation of long-term anticoagulant therapy), 
ROCKET-AF (Rivaroxaban once daily oral direct factor Xa 
inhibition compared with vitamin K antagonism for prevention of 
stroke and embolism trial in atrial fibrillation), ARISTOTLE 
(apixaban for reduction in stroke and other thromboembolic events 
in atrial fibrillation), and ENGAGE AF-TIMI 48 (Edoxaban once 
daily to prevent stroke or systemic embolism)9 have separately 
examined the long-term effect of NOACs compared with warfarin 
to prevent stroke and systemic embolism in patients with AF. 
Although these NOACs have been proved more efficacious than 
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warfarin for the primary efficacy endpoint of stroke and systemic 
embolism, the conclusion for the secondary efficacy endpoints and 
safety endpoints are heterogeneous.10,11 Therefore, it is important to 
comprehensively compare efficacy and safety of NOACs versus 
warfarin in the patients with AF. 
Several meta-analyses for NOACs versus warfarin12,13 have been 
published, but these publications included only 3 phase 3 studies: 
RE-LY, ROCKET-AF, and ARISTOTLE. In this article, except the 
above 3 studies, we added 22,385 patients by including J-ROCKET 
AF (Rivaroxaban Clinical Trial in Japan),14 and ENGAGE AF-
TIMI 48 published recently. This allowed us to perform a more 
comprehensive comparative analysis of NOACs versus warfarin. 
Moreover, different from previous analyses, we performed separate 
meta-analyses for the high-dose groups of RE-LY (150 mg twice 
daily) and ENGAGE AF-TIMI 48 (60 mg twice daily) combined 
with the single dose studies ARISTOTLE, ROCKET-AF, and J-
ROCKET AF and the low-dose groups of RE-LY (110 mg twice 
daily) and ENGAGE AF-TIMI 48 (30 mg twice daily), 
respectively. This will not merge the benefit and risk of different 
doses. 
Although with a reduced INR target level of 1.6–2.6 in J-ROCKET 
AF than the regular therapeutic range 2.0–3.0,15 the design was 
similar and the results were consistent with those of ROCKET AF 
for the primary efficacy endpoint, principal safety outcome, and 
major bleeding. Therefore, to include J-ROCKET AF in the meta-
analysis would not introduce bias. 
 
METHODS   
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Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
We systematically searched the publications of RCTs comparing 
NOACs to warfarin in patients with AF from the Cochrane Library, 
Embase, MEDLINE, Science Citation Index Expanded, and 
ProQuest in December 2013. The keywords or medical terms 
included “new oral anticoagulants,” “oral thrombin inhibitors,” 
“oral factor Xa inhibitors,” “DABIGATRAN,” 
“RIVAROXABAN,” “APIXABAN,” “EDOXABAN,” 
“BETRIXABAN,” “YM-150,” “RE-LY,” “LY-517717,” 
“ENGAGE AF-TIMI 48,” and “WARFARIN.” We only searched 
clinical trials from the Embase and MEDLINE. The Science 
Citation Index Expanded and ProQuest searches were limited to the 
reports with full-text available. In addition, we manually searched 
the clinical databases such as the website of ClinicalTrials, related 
review, and reports for further eligible studies. Two authors 
selected the studies independently, and the disagreements were 
resolved by discussion among all the authors. 
 
 
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 
giving rationale.  
 
The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement for reporting systematic reviews 
and meta-analyses of RCTs was used for this analysis.16 The 
criteria for studies included in our analysis were as following: (1) 
they were RCTs between NOACs and warfarin, (2) all the patients 
were randomized to warfarin or NOACs, and (3) the target 
population was the patients with AF. Except double-blinded, the 
open-label studies were also included in the search because of the 
need of frequent INR monitoring for warfarin. The data extracted 
from these studies included patients' age, median follow-up time, 
mean CHADS2 [congestive heart failure, hypertension, age ≥75 
years, biabetes mellitus, stroke (doubled)] scores,17 gender, mean 
time in the therapeutic range of warfarin, and some specific 
medical history. For all the included studies, the primary efficacy 
endpoint was composite of stroke and systemic embolism. The 
secondary efficacy endpoints included ischemic stroke, 
hemorrhagic stroke, all-cause mortality, and myocardial infraction. 
For safety evaluation, the main endpoint was major bleeding 
defined as fatal bleeding or bleeding in a critical site, and the 
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secondary endpoint included gastrointestinal and intracranial 
bleeding. We only considered the studies approved or in 
development so the studies for ximelagatran, which had been 
withdrawn,18 and studies for darexaban, which is no longer in 
development19 were excluded from our analysis. 
 
Information 
sources  
7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
We systematically searched the publications of RCTs comparing 
NOACs to warfarin in patients with AF from the Cochrane Library, 
Embase, MEDLINE, Science Citation Index Expanded, and 
ProQuest in December 2013. The keywords or medical terms 
included “new oral anticoagulants,” “oral thrombin inhibitors,” 
“oral factor Xa inhibitors,” “DABIGATRAN,” 
“RIVAROXABAN,” “APIXABAN,” “EDOXABAN,” 
“BETRIXABAN,” “YM-150,” “RE-LY,” “LY-517717,” 
“ENGAGE AF-TIMI 48,” and “WARFARIN.” We only searched 
clinical trials from the Embase and MEDLINE. The Science 
Citation Index Expanded and ProQuest searches were limited to the 
reports with full-text available. In addition, we manually searched 
the clinical databases such as the website of ClinicalTrials, related 
review, and reports for further eligible studies. Two authors 
selected the studies independently, and the disagreements were 
resolved by discussion among all the authors. 
 
 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
We systematically searched the publications of RCTs comparing 
NOACs to warfarin in patients with AF from the Cochrane Library, 
Embase, MEDLINE, Science Citation Index Expanded, and 
ProQuest in December 2013. The keywords or medical terms 
included “new oral anticoagulants,” “oral thrombin inhibitors,” 
“oral factor Xa inhibitors,” “DABIGATRAN,” 
“RIVAROXABAN,” “APIXABAN,” “EDOXABAN,” 
“BETRIXABAN,” “YM-150,” “RE-LY,” “LY-517717,” 
“ENGAGE AF-TIMI 48,” and “WARFARIN.” We only searched 
clinical trials from the Embase and MEDLINE. The Science 
Citation Index Expanded and ProQuest searches were limited to the 
reports with full-text available. In addition, we manually searched 
the clinical databases such as the website of ClinicalTrials, related 
review, and reports for further eligible studies. Two authors 
selected the studies independently, and the disagreements were 
resolved by discussion among all the authors. 
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Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement for reporting systematic reviews 
and meta-analyses of RCTs was used for this analysis.16 The 
criteria for studies included in our analysis were as following: (1) 
they were RCTs between NOACs and warfarin, (2) all the patients 
were randomized to warfarin or NOACs, and (3) the target 
population was the patients with AF. Except double-blinded, the 
open-label studies were also included in the search because of the 
need of frequent INR monitoring for warfarin. The data extracted 
from these studies included patients' age, median follow-up time, 
mean CHADS2 [congestive heart failure, hypertension, age ≥75 
years, biabetes mellitus, stroke (doubled)] scores,17 gender, mean 
time in the therapeutic range of warfarin, and some specific 
medical history. For all the included studies, the primary efficacy 
endpoint was composite of stroke and systemic embolism. The 
secondary efficacy endpoints included ischemic stroke, 
hemorrhagic stroke, all-cause mortality, and myocardial infraction. 
For safety evaluation, the main endpoint was major bleeding 
defined as fatal bleeding or bleeding in a critical site, and the 
secondary endpoint included gastrointestinal and intracranial 
bleeding. We only considered the studies approved or in 
development so the studies for ximelagatran, which had been 
withdrawn,18 and studies for darexaban, which is no longer in 
development19 were excluded from our analysis. 
The Cochrane Collaboration's tool was used to conduct quality 
assessment to risk of bias.
20
 It evaluated bias in a RCT within the 
following domains: sequence generation; allocation concealment; 
blinding of participants, personal, and outcome assessors; 
incomplete outcome data; selective outcome reporting; and other 
potential threats to validity. In each domain, the risk of bias was 
classified into high, low, or unclear for each RCT. 
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Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
We systematically searched the publications of RCTs comparing 
NOACs to warfarin in patients with AF from the Cochrane Library, 
Embase, MEDLINE, Science Citation Index Expanded, and 
ProQuest in December 2013. The keywords or medical terms 
included “new oral anticoagulants,” “oral thrombin inhibitors,” 
“oral factor Xa inhibitors,” “DABIGATRAN,” 
“RIVAROXABAN,” “APIXABAN,” “EDOXABAN,” 
“BETRIXABAN,” “YM-150,” “RE-LY,” “LY-517717,” 
“ENGAGE AF-TIMI 48,” and “WARFARIN.” We only searched 
clinical trials from the Embase and MEDLINE. The Science 
Citation Index Expanded and ProQuest searches were limited to the 
reports with full-text available. In addition, we manually searched 
the clinical databases such as the website of ClinicalTrials, related 
review, and reports for further eligible studies. Two authors 
selected the studies independently, and the disagreements were 
resolved by discussion among all the authors. 
 
 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
 
We systematically searched the publications of RCTs comparing 
NOACs to warfarin in patients with AF from the Cochrane Library, 
Embase, MEDLINE, Science Citation Index Expanded, and 
ProQuest in December 2013. The keywords or medical terms 
included “new oral anticoagulants,” “oral thrombin inhibitors,” 
“oral factor Xa inhibitors,” “DABIGATRAN,” 
“RIVAROXABAN,” “APIXABAN,” “EDOXABAN,” 
“BETRIXABAN,” “YM-150,” “RE-LY,” “LY-517717,” 
“ENGAGE AF-TIMI 48,” and “WARFARIN.” We only searched 
clinical trials from the Embase and MEDLINE. The Science 
Citation Index Expanded and ProQuest searches were limited to the 
reports with full-text available. In addition, we manually searched 
the clinical databases such as the website of ClinicalTrials, related 
review, and reports for further eligible studies. Two authors 
selected the studies independently, and the disagreements were 
resolved by discussion among all the authors. 
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Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this was 
done at the study or outcome level), and how this information 
is to be used in any data synthesis.  
The Cochrane Collaboration's tool was used to conduct quality 
assessment to risk of bias.20 It evaluated bias in a RCT within the 
following domains: sequence generation; allocation concealment; 
blinding of participants, personal, and outcome assessors; 
incomplete outcome data; selective outcome reporting; and other 
potential threats to validity. In each domain, the risk of bias was 
classified into high, low, or unclear for each RCT. 
 
 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
 
Based on the random-effects model by DerSimonian and 
Laird,21 we calculated the pooled relative risks (RRs) and their 
corresponding 95% confidence intervals (CIs).  
 
Synthesis of 
results  
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
 
The presence of between-study variability was assessed by the Q 
statistic (P < 0.10 was used as indicator of statistically significant 
result), and the proportion of heterogeneity was assessed by the 
I2 index. All the analyses were conducted in statistical software 
Stata 11.0 (StataCorp LP, College Station, TX). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section/topic  # Checklist item  
Reported 
on page 
#  
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Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
The Cochrane Collaboration's tool was used to conduct quality 
assessment to risk of bias.20 It evaluated bias in a RCT within the 
following domains: sequence generation; allocation concealment; 
blinding of participants, personal, and outcome assessors; 
incomplete outcome data; selective outcome reporting; and other 
potential threats to validity. In each domain, the risk of bias was 
classified into high, low, or unclear for each RCT. 
 
 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
 
Eight hundred nine publications were identified though database 
search (Fig. 1). By study selection process, the 5 studies from 56 
publications (ARISTOTLE, ENGAGE AF-TIMI 48, RE-LY, 
ROCKET-AF, and J-ROCKET) assessing the efficacy and safety 
of NOACs compared with warfarin in patients with AF were 
evaluated for eligibility. The primary objective was to determine 
whether the new drug was noninferior to warfarin about the 
composite of stroke and systemic embolism. 
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Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
 
Forty-three thousand fifty patients received NOACs and 29,911 
received warfarin. Baseline characteristics of the populations are 
listed in Table 1. The average age and proportion of female were 
similar between NOACs and warfarin groups among the 5 studies. 
The underlying risk for stroke indicated by the proportion of 
patients with CHADS2 was significantly different across studies. It 
can be observed the studies ENGAGE AF-TIMI 48, ROCKET-AF, 
and J-ROCKET enrolled more patients with higher risk of stroke 
than ARISTOTLE and RE-LY. The median follow-up time in all 
studies ranged from 1.6 to 2.8 years, and the median time in 
therapeutic range of patients assigned to warfarin ranged from 44% 
to 68%. 
 
 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment (see item 12).  
The risk of bias was assessed by Cochrane Collaboration's tool. In 
RE-LY, dabigatran was administered in a blinded fashion, whereas 
warfarin was administered in an unblinded fashion to locally adjust 
INR within the therapeutic range 2.0–3.0. However, all the 
investigators, coordinating center members, the steering 
committee, and the sponsor were kept blinded during event 
ascertainment and analyses process.22 Therefore, the risk of bias 
due to blind was low for RE-LY. For ROCKET-AF, the efficacy 
was analyzed based on intention-to-treat and bleeding on safety 
analysis data sets (1 site including 93 patients was excluded due to 
good clinical practice violation).10 This should not introduce 
additional selection bias. 
 
 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally 
with a forest plot.  
For the high-dose regimen analysis, NOACs demonstrated 
noninferior to warfarin in the prevention of stroke and systemic 
embolism in each study. NOACs further demonstrated superior to 
warfarin at the above endpoint in ARISTOTLE and RE-LY (Fig. 
2). In respect to the major bleeding prevention, NOACs showed 
superiority to warfarin in ARISTOTLE and ENGAGE AF-TIMI 
48, whereas other studies showed comparable risk of major 
bleeding (Fig. 3). The pooled risk of stroke and systemic embolism 
in the patients randomized to NOACs was 20% lower (RR = 0.80; 
95% CI, 0.71–0.91) than those randomized to warfarin. This 
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benefit was mostly driven by the large reduction of hemorrhagic 
stroke (RR = 0.50; 95% CI, 0.41–0.62) and the reduction of all-
cause mortality (RR = 0.90; 95% CI, 0.85–0.95). For safety, the 
pooled risk of major bleeding events in the patients randomized to 
NOACs was reduced by 14% (RR = 0.86; 95% CI, 0.74–0.99) 
compared with the risk of those on warfarin because of the large 
reduction of intracranial hemorrhage (RR = 0.48; 95% CI, 0.41–
0.56) (Fig. 4). 
For the low-dose regimen meta-analysis, NOACs demonstrated 
similar efficacy to warfarin for prevention of stroke and systemic 
embolism in each study. The similar conclusion was drawn for the 
pooled group (RR = 1.03; 95% CI, 0.84–1.27). If differentiated by 
stroke types, the large reduction in the risk of hemorrhagic stroke 
(RR = 0.33; 95% CI, 0.23–0.46) was offset by the increase in 
ischemic stroke (RR = 1.31; 95% CI, 1.14–1.49). For low-dose 
regimens, there was also a reduction in the risk of all-cause 
mortality (RR = 0.89; 95% CI, 0.83–0.96) but a higher risk of 
myocardial infarction (RR = 1.25; 95% CI, 1.04–1.50). For safety, 
although with the significant difference for the risk of major 
bleeding events in each study, the pooled RR of NOACs compared 
with warfarin (RR = 0.63; 95% CI, 0.38–1.04) was inconclusive. 
When differentiated by bleeding types, there was a large risk of 
decrease in intracranial hemorrhage (RR = 0.31; 95% CI, 0.24–
0.41) and also a risk of decrease in gastrointestinal bleeding (RR = 
0.85; 95% CI, 0.72–1.00) (Fig. 5). 
 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
From the combined results of the high-dose and low-dose 
regimens, the inclusion of low-dose diminished the magnitude of 
risk reduction in stroke and systemic embolism (RR = 0.86; 95% 
CI, 0.75–0.99) by NOACs but resulting in lower risk of major 
bleeding events (RR = 0.78; 95% CI, 0.64–0.94). 
 
 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
 
DISCUSSION   
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Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy 
makers).  
 
Based on the design of each study, in this article, we considered 
meta-analyses for high-dose regimen, low-dose regimen, and their 
combination. Five phase III RCTs including ARISTOTLE, 
ENGAGE AF-TIMI 48, RE-LY, ROCKET-AF, and J-ROCKET 
were included in our analysis. It was found that randomization to 
NOACs reduced the risk of stroke and systemic embolism 
compared with warfarin. This benefit was mainly driven by the 
substantial reduction of hemorrhagic stroke. Although as a part of 
the efficacy assessment of NOACs, hemorrhagic stroke is also a 
complication of anticoagulant treatment.23 The rough half reduction 
in risk of hemorrhagic stroke by NOACs indicated the benefit of 
the treatment. NOACs were also found to be associated with lower 
risk of hemorrhagic stroke and all-cause mortality compared with 
warfarin. A lower risk in ischemic stroke (RR = 0.87; 95% CI, 
0.77–0.99) between NOACs and warfarin was reported by Miller et 
al,12 which was different from our inconclusive result. However, 
for the prevention of ischemic stroke, the NOAC is effective due to 
the reduction of the risk by two thirds compared with placebo.5 The 
pooled risk of major bleeding events was similar between NOACs 
and warfarin. The combined results of efficacy and safety support 
use of the NOACs as alternatives to warfarin for long-term 
prevention in the patients with AF. 
The separate meta-analyses of the high-dose and low-dose 
regimens showed that the high-dose regimen has better 
performance than low dose in efficacy. Although with similar risks 
of stroke and systemic embolism and major bleeding events, low-
dose regimen was found to significantly reduce the risk of 
hemorrhagic stroke, all-cause mortality, and intracranial 
hemorrhage. Consequently, the low-dose regimen could be an 
appealing option for the patients with high risk of bleeding with 
full-dose anticoagulation therapy. 
Warfarin has been underused due to concerns over the need of 
frequent INR monitoring and the risk of bleeding.24 Only about a 
half of patients with AF received warfarin. Furthermore, the 
patients receiving it might have 30%–50% of time not within the 
therapeutic range 2.0–3.0. Therefore, the development of NOACs 
seems necessary. Moreover, there are already 2 compounds 
dabigatran and rivaroxaban approved by the US Food and Drug 
Administration.25,26 It is necessary to compare them with warfarin 
on efficacy and safety by meta-analysis so that the informed 
clinical decisions can be made. 
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From the meta-analysis, we observed that the estimates are 
inconsistent across all the studies. We believe that these large 
phase III studies have enough power to evaluate the primary 
efficacy but may not have sufficient power to compare the 
secondary endpoints. Especially for the inconclusive results from 
individual study, they cannot always show us a real conclusion. 
One example is: the conclusive result for all-cause mortality is only 
benefited by apixaban and low-dose edoxaban. This also indicates 
the ability of meta-analysis in the assessment of the relative 
benefits of NOACs compared with warfarin. Another example is: 
different studies enrolled different proportions of patients with 
CHADS2 scores. It would have been difficult to provide an overall 
description for NOACs compared with warfarin on their efficacy 
and safety without performing a meta-analysis. 
Actually, by working mechanisms, rivaroxaban, apixaban, and 
edoxaban should be factor Xa inhibitors, whereas dabigatran is the 
thrombin inhibitor. A sensitivity analysis was done by excluding 
dabigatran from the high-dose regimen. The risk of stroke and 
systemic embolism (RR = 0.85; 95% CI, 0.77–0.93) was similar 
but the risk of major bleeding (RR = 0.84; 95% CI, 0.69–1.01) 
became inconclusive. However, the 5 studies could be pooled 
together for below reasons: they are all phase 3 warfarin-controlled 
trials with similar designs, and they are NOACs by specific 
inhibitors of important factors in the coagulation cascade, and 
previous meta-analyses took a similar approach.27 
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
There were 2 potential limitations for our meta-analyses: First, the 
patients in clinical trials were often at lower risk of adverse events 
than those seen in routine clinical practice. This might affect the 
generalizability of the results based on the clinical trials.28 Second, 
the patients taking warfarin in routine clinical practice often had 
less time of INR well-controlled in the therapeutic range.29 This 
variability could not be applied to the NOACs in the meta-analysis. 
 
 
Conclusions  26 Provide a general interpretation of the results in the context 
of other evidence, and implications for future research.  
In general, our meta-analyses have shown the balance between 
safety and efficacy of the NOACs compared with warfarin. 
NOACs demonstrated promising alternatives to warfarin in 
prevention of stroke in patients with AF. 
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Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
systematic review.  
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Meta-analysis No 2: 
Efficacy and Safety of the Novel Oral Anticoagulants in Atrial 
Fibrillation 
Prisma Checklist: 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
Efficacy and Safety of the Novel Oral Anticoagulants in Atrial 
Fibrillation 
A Systematic Review and Meta-Analysis of the Literature 
 
 
2381 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
Background—Novel oral anticoagulants (NOACs) have been 
proposed as alternatives to vitamin K antagonists for the prevention 
of stroke and systemic embolism in patients with atrial fibrillation. 
Individually, NOACs were at least noninferior to vitamin K 
antagonists, but a clear superiority in overall and vascular mortality 
was not consistently proven. 
Methods and Results—We performed a meta-analysis of phase II 
and phase III randomized, controlled trials comparing NOACs with 
vitamin K antagonists in patients with atrial fibrillation. The 
MEDLINE and EMBASE databases, supplemented with 
conference abstract books and www.clinicaltrials.gov, were 
searched up to the first week of July 2012 with no language 
2381 
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restriction. Two reviewers performed independent article review 
and study quality assessment. Data on overall and cardiovascular 
mortality, stroke or systemic embolism, ischemic stroke, major and 
intracranial bleeding, and myocardial infarction were collected. 
NOACs were pooled to perform a comparison with vitamin K 
antagonists, calculating pooled relative risks (RRs) and associated 
95% confidence intervals (CIs). We retrieved 12 studies (3 
administering dabigatran, 4 administering rivaroxaban, 2 
administering apixaban, and 3 administering edoxaban) enrolling a 
total of 54 875 patients. NOACs significantly reduced total 
mortality (5.61% versus 6.02%; RR, 0.89; 95% CI, 0.83–0.96), 
cardiovascular mortality (3.45% versus 3.65%; RR, 0.89; 95% CI, 
0.82–0.98), and stroke/systemic embolism (2.40% versus 3.13%; 
RR, 0.77; 95% CI, 0.70–0.86). There was a trend toward reduced 
major bleeding (RR, 0.86; 95% CI, 0.72–1.02) with a significant 
reduction of intracranial hemorrhage (RR, 0.46; 95% CI, 0.39–
0.56). No difference in myocardial infarction was observed. 
Conclusions—NOACs are associated with an overall clinical 
benefit compared with vitamin K antagonists. Additional research 
is required to confirm these findings outside the context of 
randomized trials. 
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
Atrial fibrillation (AF) is the most common cardiac arrhythmia, 
with an overall prevalence of 5.5% that increases up to 17.8% in 
individuals ≥85 years of age.1 AF is a major risk factor for 
stroke,2 with a 30-day mortality rate of 24% in the absence of 
treatment.3 
Clinical Perspective on p 2391 
Vitamin K antagonists (VKAs) are highly effective for the 
prevention of stroke, mainly of ischemic origin, in patients with 
AF, resulting in a 64% risk reduction compared with placebo and a 
37% risk reduction compared with antiplatelet therapy.4 For this 
reason, VKAs are currently recommended in all AF patients at 
moderate to high risk for stroke or systemic embolism 
(SE).5 However, VKAs have significant limitations, particularly 
their unpredictable anticoagulant response and numerous food and 
drug interactions, mandating regular laboratory monitoring.6 These 
limitations make treatment with VKAs problematic for many 
patients; as a result, only about half of all potentially eligible AF 
patients are treated with VKAs.6 
Over the last several years, novel oral anticoagulant drugs 
(NOACs), including direct thrombin inhibitors and factor Xa 
inhibitors, have been developed. These drugs have the potential to 
address some of the limitations of VKAs.7 These agents have fewer 
food and drug interactions and a more predictable anticoagulant 
effect, thus allowing fixed dosing without the need for laboratory 
2381, 
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monitoring. Furthermore, their shorter half-life may produce 
additional advantages, eg, if temporary interruption is required for 
a surgical procedure or in the case of an hemorrhagic complication. 
The NOACs have been compared with warfarin for the prevention 
of stroke and SE in patients with AF.8–10 These trials have been 
favorable for the NOACs but have not consistently demonstrated 
superiority over warfarin, particularly in terms of overall and 
vascular mortality.  
 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
To better assess the clinical benefit, we carried out a systematic 
review of the literature and a meta-analysis of phase II and phase 
III randomized, clinical trials (RCTs) of these agents compared with 
VKAs for the prevention of stroke or SE in patients with AF. 
2382 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
A protocol for this review was prospectively developed that 
detailed the specific objectives, criteria for study selection, 
approach to assess study quality, outcomes, and statistical 
methods. This protocol is available for review through the 
investigators. 
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Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 
giving rationale.  
 
Two reviewers (N.R. and F.D.) performed study selection 
independently, with disagreements solved through discussion and 
by the opinion of a third reviewer (W.A.) if necessary. Studies 
were considered potentially eligible for this systematic review if 
they met the following criteria: They were phase III RCTs or phase 
II RCTs including at least one of the evaluated dosages 
subsequently used in phase III trials; NOACs were compared with 
therapeutic doses of VKAs in patients with AF; and 
thromboembolic and bleeding events were objectively assessed in 
both groups. 
For trials that were reported in >1 publication, we extracted data 
from the most complete publication and used other publications to 
clarify data. 
To assess the agreement between reviewers for study selection, we 
used the κ statistic, which measures agreement beyond chance.11 
 
2382 
Information 
sources  
7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
We identified all published studies that compared the risk of 
thromboembolic and/or major bleeding (MB) events in AF 
patients randomized to VKAs (warfarin, phenprocoumon, 
acenocumarol, fluindione, and tecarfarin) or NOACs (dabigatran, 
AZD0837, sofigatran, rivaroxaban, apixaban, edoxaban, 
betrixaban, eribaxaban, LY517717, YM150, TAK442, and TTP889) 
using the MEDLINE (1966 to week 1 of July 2012) and the EMBASE 
(1980 to week 1 of July 2012) electronic databases. The term 
ximelagatran was excluded from the search because this drug has 
been withdrawn from the market 
2382 
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Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
The search strategy was developed without any language 
restriction and used the medical subject headings and text words 
presented in Table 1 in the online-only Data Supplement. We 
supplemented our search by reviewing abstracts books from the 
congresses of the International Society on Thrombosis and 
Haemostasis (2003–2011), European Society of Cardiology (2005–
2011), American Society of Hematology (2004–2011), and 
American College of Cardiology (2008–2011) and by manually 
reviewing the reference lists of all retrieved articles. We also 
searched on the www.clinicaltrials.gov Web site to identify 
unpublished trials. 
 
2382 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
Two reviewers (N.R. and F.D.) performed study selection 
independently, with disagreements solved through discussion and 
by the opinion of a third reviewer (W.A.) if necessary. Studies 
were considered potentially eligible for this systematic review if 
they met the following criteria: They were phase III RCTs or phase 
II RCTs including at least one of the evaluated dosages 
subsequently used in phase III trials; NOACs were compared with 
therapeutic doses of VKAs in patients with AF; and 
thromboembolic and bleeding events were objectively assessed in 
both groups. 
For trials that were reported in >1 publication, we extracted data 
from the most complete publication and used other publications to 
clarify data. 
To assess the agreement between reviewers for study selection, we 
used the κ statistic, which measures agreement beyond chance.11 
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Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
 
We extracted and presented data according to the Providing 
Innovative Service Models and Assessment (PRISMA) criteria.12 If 
outcome data for extraction could not be identified, we contacted 
the study authors by e-mail, with a reminder after 15 days. For 
unpublished trials, we also contacted the pharmaceutical 
companies. 
Two reviewers (N.R. and F.D.) independently assessed study 
quality using a validated scale14 based on the following criteria: 
methods used to generate the randomization sequence, method of 
double blinding, and description of patient withdrawals and 
dropouts. A score of 1 point was given for each criterion satisfied, 
and 1 additional point was given for high quality of randomization 
and double blinding, for a maximum of 5 points. Studies with a 
score >2 were considered high quality, and studies with a score ≤2 
were considered low quality. Although concealed treatment 
allocation is not part of this rating scale, it was included in our 
study quality assessment. 
We resolved disagreements about study data extraction by 
consensus or by discussion with a third reviewer (W.A.). 
 
2382 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
 
 Two reviewers (N.R. and F.D.) independently extracted data on 
study (year of publication, design), population characteristics 
(number of patients, mean age, sex), and treatment (therapeutic 
indication, type of drug, dose, and duration). 
Information on the following outcomes was collected in the 2 
groups: number of total and ischemic strokes (ISs), SE, total and 
cardiovascular mortality, MB and intracranial bleeding, and 
myocardial infarctions (MIs). No attempt was made to reclassify 
bleeding events. However, in the included studies, MBs were 
classified mostly according to International Society on Thrombosis 
and Haemostasis criteria13 as bleeding causing a fall in hemoglobin 
levels of ≥2 g/dL, bleeding leading to transfusion of ≥2 U whole 
blood or red cells, symptomatic bleeding in a critical area 
(intracranial, intraspinal, intraocular, retroperitoneal, intrarticular, 
pericardial, or intramuscular with compartment syndrome), or 
bleeding events leading to death. 
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Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this was 
done at the study or outcome level), and how this information 
is to be used in any data synthesis.  
The presence of publication bias was investigated by the use of 
funnel plots of effect size versus standard error.
20
 
2382 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
We determined pooled relative risks (RRs) and corresponding 95% 
confidence intervals (CIs) for all-cause and cardiovascular 
mortality in AF patients who received VKAs or treatment with a 
NOAC. Furthermore, the pooled RR of any cardioembolic event 
(which included stroke or SE), IS, MB and intracranial bleeding, 
and MI in the 2 arms of treatment was calculated. Because 
transient ischemic attacks are frequently subjective, seldom 
consistently reported, and not usually considered a primary 
outcome in AF trials, we decided not to include them in our 
analysis. 
 
2382 
Synthesis of 
results  
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
From phase II dose-ranging RCTs, we summed all groups whose 
total daily dose was equal to the regimens used in phase III RCTs. 
For all the treatment effects that were statistically significant, we 
determined the absolute risk reduction (ARR) or the absolute risk 
increase and the corresponding number needed to treat (NNT) or 
number needed to harm. Data were pooled by use of a fixed-
effects model (Mantel-Haenszel method),
15
 and results were 
compared with the results obtained with a random-effects (RE) 
model (DerSimonian-Laird method).
16
 A value of P<0.05 was 
considered statistically significant. All analyses were performed 
with Review-Manager software (RevMan, version 5.1.6 for 
Windows; The Cochrane Collaboration, Oxford, UK; 2008). 
Because combining trials with extremely low or zero event rates 
can yield biased results, we repeated the analyses using 
Comprehensive Meta-Analysis software, version 2 (Biostat 
Software Corp, Englewood, NJ), which provides exact fixed-effect 
point and interval estimates for the odds ratio.17 The 
appropriateness of pooling data across studies was assessed with 
the use of the Cochran Q and the I
2
 test for heterogeneity, which 
measures the inconsistency across study results and describes the 
proportion of total variation in study estimates that is due to 
heterogeneity rather than sampling error.18 For the preparation of 
the forest plots, we also used the Meta Data Viewer software 
version 1.02 (National Toxicology Program, Research Triangle 
Park, NC).
19
 The presence of publication bias was investigated by 
the use of funnel plots of effect size versus standard error.
20
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Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
The presence of publication bias was investigated by the use of 
funnel plots of effect size versus standard error.
20
 
2382 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
Sensitivity Analyses 
We repeated sensitivity analyses by using only studies that satisfied 
each item of our prespecified quality evaluation.21 Furthermore, 
separate analyses of studies published in peer-reviewed journals 
were provided. 
Subgroup Analyses 
We planned to perform separate analyses of studies assessing 
short-term outcomes (1–3 months) and long-term outcomes (>1 
year). 
We also performed separate analyses including, from phase II 
trials, only the exact same dose regimen of the NOAC that was 
subsequently used in phase III trials and, in a separate analysis, 
excluding the lower dosage of dabigatran (110 mg twice daily), 
which is not licensed by the US Food and Drug Administration. 
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Study selection  17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
We identified 1454 potentially relevant studies: 364 from 
MEDLINE and 1090 from EMBASE. A total of 317 studies were 
duplicated, and 1106 studies were excluded after title and abstract 
screening. The remaining 31 studies were retrieved in full for 
detailed evaluation. A list of the 24 excluded studies and reasons 
for exclusion is available on request. Two additional studies were 
identified from a personal library.22,23 We identified 3 more studies 
by searching unpublished trials on www.clinicaltrials.gov.24–26 A 
review of the reference lists of included studies did not provide any 
additional references. Twelve studies were therefore included in 
this systematic review.8–10,22–30 Interobserver agreement for study 
selection was almost perfect (κ=0.89). The study identification and 
selection progression are summarized in Figure I in the online-only 
Data Supplement. 
Data from 2 studies were supplemented with information extracted 
from more recent publications.31,32 Supplementary data for 7 trials 
were provided by the investigators involved in the trial or the 
pharmaceutical companies.22–27,29 Data on dabigatran and 
rivaroxaban were also supplemented with information from their 
Food and Drug Administration reviews.33,34 
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Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
Baseline characteristics of patients included in the studies are 
summarized in the Table. For 4 NOACs (apixaban, dabigatran, 
edoxaban, and rivaroxaban), a phase III RCT was published or was 
ongoing. The comparator VKA was warfarin in all studies. All 
studies were published in English. Study size ranged from 100 
patients26 to 18 201 patients,10 for a total of 54 875 included 
patients. Eight studies were phase II RCTs22,24–30 and 4 studies 
were phase III RCTs.8–10,23 Three studies involved 
dabigatran,8,24,30 4 involved rivaroxaban,9,23,25,26 2 involved 
apixaban,10,27 and 3 involved edoxaban.22,28,29 
 
 
 
2383 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment (see item 12).  
 
The presence of publication bias was investigated by the use 
of funnel plots of effect size versus standard error. 
 
2382 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally 
with a forest plot.  
 
 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
 
 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
Sensitivity Analyses 
Sensitivity analyses including only high-quality8–10,23,28.29 and 
published8–10,22.23,27–30 studies confirmed the results of the primary 
analyses (Figures IV–VII in the online-only Data Supplement). 
Similarly, repeating our analyses with Comprehensive Meta 
Analysis software including trials with extremely low or zero event 
rates did not change the results of the primary analyses (results 
available on request). 
Subgroup Analyses 
2385, 
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In the subgroup analysis that included only studies with short-term 
follow-up,22,24–30 only the rate of stroke and SE appears to be 
significantly reduced in patients randomized to NOACs, whereas 
the rates of cardiovascular and total death, IS, MB, intracranial 
bleeding, and MI were similar in the 2 groups. In contrast, the 
subgroup analyses that included only studies with long-term 
follow-up8–10,23 and only the dose regimens used in phase III 
studies provided the same results as the primary analyses. 
The analysis excluding the lower dosage of dabigatran showed a 
reduction of IS with NOACs compared with VKAs (RR, 0.86; 95% 
CI, 0.76–0.99; I2=30%) using a fixed-effects model. This result 
was not statistically significant with an RE model (RR, 0.85; 95% 
CI, 0.70–1.02; Figures IV–VII in the online-only Data 
Supplement). 
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Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy 
makers).  
 
 
This is, to the best of our knowledge, the first systematic review 
and meta-analysis of phase II and phase III RCTs that compared 
the NOACs with warfarin for the prevention of stroke and SE in 
patients with AF. Our analysis, incorporating >50 000 patients, 
found a statistically significant 11% RR reduction in the incidence 
of both total mortality and cardiovascular mortality, which 
corresponds to an NNT of 244 patients to prevent 1 death and to an 
NNT of 500 patients to prevent 1 cardiovascular death. The 
observed advantage of the NOACs is consistent for all outcomes, 
including stroke and SE reduction (RR reduction, 23%; NNT, 137) 
and MB reduction (RR reduction, 14%; NNT, 157). 
Following the favorable results of the individual clinical trials, 
dabigatran and rivaroxaban have received approval from the 
regulatory agencies and apixaban is expected to be licensed in the 
near future. However, the cost-effectiveness of these compounds 
remains unclear. This lack of clarity exists, in part, as a result of the 
observation that single studies have reported small and often 
nonstatistically significant differences between the NOACs and 
warfarin for hard end points such as overall mortality and vascular 
mortality. 
We believe that our study could provide more accurate estimates of 
the expected clinical benefits of the NOACs. Taken together, our 
results suggest that the use of the NOACs not only provides 
practical advantages over the VKAs but also is associated with an 
overall clinical benefit, suggesting their cost-effectiveness. 
More important, the NOACs both reduce clinical events and offer 
the possibility of increasing the use of adequate prophylactic 
strategies in patients with AF. It is well known that AF remains a 
major cause of stroke2 and that the severity of stroke is greater in 
patients with AF than in other subgroups.35 Despite this evidence, 
the use of VKAs in the real world of patients with AF remains 
unacceptably low, with an overall prevalence of treated high-risk 
patients not exceeding 70%.36 The availability of NOACs has the 
potential to reduce the incidence of AF-related strokes and SE 
because of both their superior efficacy and their potential to be 
more widely used compared with the VKAs. 
In this meta-analysis, we have combined the results of clinical 
2386, 
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trials carried out with 4 NOACs. These drugs present some 
important differences in terms of mechanisms of action; 1 drug 
(dabigatran etexilate) is a direct thrombin inhibitor and 3 drugs 
(rivaroxaban, apixaban, and edoxaban) are direct factor Xa 
inhibitors. Moreover, there are some differences in the mechanisms 
of excretion, in their mean half-lives, and in the drug-drug 
interactions, among others.37 These differences may suggest that 
combining the results of these drugs may not be appropriate. 
However, there were no signs of heterogeneity when the outcomes 
of total and cardiovascular mortality, stroke, or SE were analyzed, 
thus suggesting that the advantages in terms of efficacy are 
consistent among all the new agents included in our study. On the 
other hand, significant heterogeneity was documented when the 
outcome of MB was analyzed. 
This finding may be due in part to some drug-specific or regimen-
specific differences in terms of safety, although none of the 
NOACs were less safe than warfarin, and to patient-specific 
characteristics. Indeed, some studies enrolled an intermediate-risk 
population with a mean CHADS2 score of ≈2,
8,10,22,27–29 whereas 
other studies enrolled a population at higher risk not only for 
thromboembolic but also for bleeding complications, with a mean 
CHADS2 score >3.
9,23 
When the analysis was repeated with the exclusion of the lower 
dose of dabigatran, which is not approved in the United States and 
is recommended for more fragile patients in other countries, the 
results were fully comparable to those of the main analysis in terms 
of total mortality and safety, whereas a tendency toward a greater 
benefit in the reduction of IS was observed. 
There is great interest in the potential increased risk of MI with the 
use of the NOACs, particularly dabigatran. The results of a recent 
meta-analysis of trials involving dabigatran for the primary and 
secondary prevention of cardiovascular diseases found a 33% RR 
increase in acute coronary events with the novel direct thrombin 
inhibitors compared with traditional anticoagulant drugs.38 Another 
recent analysis comparing warfarin with other antithrombotic drugs 
(ximelagatran, dabigatran, idraparinux, and clopidogrel) in AF 
clinical trials found a 23% RR reduction in the rate of MI with 
warfarin, suggesting the protective effect of the VKA.39 In this 
meta-analysis, we failed to detect any difference in the overall risk 
of MI, with a 1.29% rate in both NOAC- and VKA-treated patients. 
Of interest, no statistically significant difference was detected after 
subgroup analysis. 
The strengths of this study include the rigorous methodological 
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approach, the selection of all the studies performed with the 4 
NOACs considered, and the consistency of the results of sensitivity 
analyses. Furthermore, to the greatest extent possible, we confined 
our analysis to clinically relevant events, and because all the 
studies were performed as a component of product registration, it is 
likely that all reported outcome events were objectively confirmed. 
 
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
The study has a number of limitations. First, because this was a 
study-level meta-analysis, we were unable to confirm the overall 
results in specific subgroups of patients according to their baseline 
stroke or bleeding risk. Population characteristics were quite 
different among the single studies; however, several subgroup 
analyses have already been published suggesting the consistency of 
the principal findings across different subgroups such as patients 
with previous stroke31,40.41 or more advanced age.42 Second, we 
could not compare the patients receiving NOACs with different 
subgroups of warfarin-treated patients according to the time in 
therapeutic range, and it has been shown that the magnitude of the 
2389 
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benefit of the NOACs compared with standard treatment is 
dependent on the quality of control of warfarin.43 Third, the results 
of our meta-analysis are driven mainly by 3 large RCTs involving 
dabigatran,8 rivaroxaban,9 and apixaban,10 whereas fewer data are 
available on edoxaban because the phase III RCT is currently 
ongoing. Fourth, the funnel plot for stroke or SE was asymmetrical 
with a lack of studies on the right part of the plot, suggesting that 
unpublished studies likely to demonstrate an increased risk of 
stroke or SE with NOACs were not included in our meta-analysis. 
Instead, the funnel plot for MI was lacking studies on the left side 
of the plot, suggesting that studies demonstrating a reduction in the 
risk of MI with NOACs were not included. However, because we 
performed an extensive research of the literature, including 
abstracts presented at congresses of several international societies, 
and because we contacted pharmaceutical companies asking for 
unpublished trials, the existence of other trials not included in our 
systematic review is extremely unlikely. 
 
Conclusions  26 Provide a general interpretation of the results in the context 
of other evidence, and implications for future research.  
NOACs reduced overall and cardiovascular mortality, stroke and 
SE, and MB and intracranial bleeding compared with warfarin. 
These favorable efficacy and safety profiles now need to be 
confirmed in postmarketing studies. 
2389 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
systematic review.  
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at McMaster University. Dr Crowther's institution has received 
funding for research projects from Boehringer Ingelheim, 
Octapharm, Pfizer, and Leo Pharma. Dr Lip has served as a 
consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, 
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for speaking activities from Boehringer Ingelheim, Bayer, BMS, 
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Meta-analysis No3: 
Comparison of the efficacy and safety of new oral 
anticoagulants with warfarin in patients with atrial fibrillation: a 
meta-analysis of randomised trials 
The access to the full article of this meta-analysis is not free, so we can only assess its 
title and summary. 
Prisma Checklist: 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
Comparison of the efficacy and safety of new oral anticoagulants 
with warfarin in patients with atrial fibrillation: a meta-analysis of 
randomised trials 
 
 
 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
Background 
Four new oral anticoagulants compare favourably with warfarin for 
stroke prevention in patients with atrial fibrillation; however, the 
balance between efficacy and safety in subgroups needs better 
definition. We aimed to assess the relative benefit of new oral 
anticoagulants in key subgroups, and the effects on important 
secondary outcomes. 
Methods 
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We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting 
searches to phase 3, randomised trials of patients with atrial 
fibrillation who were randomised to receive new oral 
anticoagulants or warfarin, and trials in which both efficacy and 
safety outcomes were reported. We did a prespecified meta-
analysis of all 71 683 participants included in the RE-LY, 
ROCKET AF, ARISTOTLE, and ENGAGE AF–TIMI 48 trials. 
The main outcomes were stroke and systemic embolic events, 
ischaemic stroke, haemorrhagic stroke, all-cause mortality, 
myocardial infarction, major bleeding, intracranial haemorrhage, 
and gastrointestinal bleeding. We calculated relative risks (RRs) 
and 95% CIs for each outcome. We did subgroup analyses to assess 
whether differences in patient and trial characteristics affected 
outcomes. We used a random-effects model to compare pooled 
outcomes and tested for heterogeneity. 
Findings 
42  411 participants received a new oral anticoagulant and 29 272 
participants received warfarin. New oral anticoagulants 
significantly reduced stroke or systemic embolic events by 19% 
compared with warfarin (RR 0·81, 95% CI 0·73–0·91; p<0·0001), 
mainly driven by a reduction in haemorrhagic stroke (0·49, 0·38–
0·64; p<0·0001). New oral anticoagulants also significantly 
reduced all-cause mortality (0·90, 0·85–0·95; p=0·0003) and 
intracranial haemorrhage (0·48, 0·39–0·59; p<0·0001), but 
increased gastrointestinal bleeding (1·25, 1·01–1·55; p=0·04). We 
noted no heterogeneity for stroke or systemic embolic events in 
important subgroups, but there was a greater relative reduction in 
major bleeding with new oral anticoagulants when the centre-based 
time in therapeutic range was less than 66% than when it was 66% 
or more (0·69, 0·59–0·81 vs 0·93, 0·76–1·13; p for interaction 
0·022). Low-dose new oral anticoagulant regimens showed similar 
overall reductions in stroke or systemic embolic events to warfarin 
(1·03, 0·84–1·27; p=0·74), and a more favourable bleeding profile 
(0·65, 0·43–1·00; p=0·05), but significantly more ischaemic 
strokes (1·28, 1·02–1·60; p=0·045). 
Interpretation 
This meta-analysis is the first to include data for all four new oral 
anticoagulants studied in the pivotal phase 3 clinical trials for 
stroke prevention or systemic embolic events in patients with atrial 
fibrillation. New oral anticoagulants had a favourable risk–benefit 
profile, with significant reductions in stroke, intracranial 
haemorrhage, and mortality, and with similar major bleeding as for 
warfarin, but increased gastrointestinal bleeding. The relative 
efficacy and safety of new oral anticoagulants was consistent 
across a wide range of patients. Our findings offer clinicians a 
more comprehensive picture of the new oral anticoagulants as a 
therapeutic option to reduce the risk of stroke in this patient 
population. 
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None. 
 
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
 
 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
 
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 
giving rationale.  
 
 
 
Information 
sources  
7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
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Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
 
 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
 
 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
 
 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
 
 
 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this was 
done at the study or outcome level), and how this information 
is to be used in any data synthesis.  
 
 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
 
 
Synthesis of 
results  
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section/topic  # Checklist item  
Reported 
on page 
#  
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 12:48:21 EET - 137.108.70.7
37 
 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
 
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
 
 
 
 
 
 
 
 
 
 
 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
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Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment (see item 12).  
 
 
 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally 
with a forest plot.  
 
 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
 
 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
 
 
DISCUSSION   
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Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy 
makers).  
 
 
 
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
 
Conclusions  26 Provide a general interpretation of the results in the context 
of other evidence, and implications for future research.  
 
 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
systematic review.  
 
 
 
 
Meta-analysis No4: 
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Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, 
Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation 
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Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants 
(Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients 
With Atrial Fibrillation 
 
 
 
 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
New oral anticoagulants are categorized, on the basis of their 
targets, as direct thrombin or factor Xa inhibitors.1 Direct thrombin 
inhibitors include AZD0837 and dabigatran, and direct factor Xa 
inhibitors include apixaban, betrixaban, edoxaban, LY-517717, 
rivaroxaban, and ym-150. Recently, 3 large phase III randomized 
controlled trials (RCTs), the Apixaban for Reduction of Stroke and 
Other Thromboembolic Events in Atrial Fibrillation 
(ARISTOTLE) trial,2 the Randomized Evaluation of Long-Term 
Anticoagulation Therapy (RE-LY) trial,3 and the Rivaroxaban 
Once Daily Oral Direct Factor Xa Inhibition Compared With 
Vitamin K Antagonism for Prevention of Stroke and Embolism 
Trial in Atrial Fibrillation (ROCKET AF),4 have examined the 
long-term use of new oral anticoagulants. Although these trials 
established that new oral anticoagulants were more efficacious than 
warfarin with respect to the primary end point of combined stroke 
and systemic embolism, their results pertaining to important 
secondary efficacy end points as well as safety outcomes were 
inconclusive or heterogenous. We therefore performed a systematic 
review and meta-analysis to examine the long-term efficacy and 
safety of the new oral anticoagulants compared to warfarin in 
preventing stroke and systemic embolism in patients with atrial 
fibrillation (AF). 
 
 
 
INTRODUCTION   
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Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
We therefore performed a systematic review and meta-analysis to 
examine the long-term efficacy and safety of the new oral 
anticoagulants compared to warfarin in preventing stroke and 
systemic embolism in patients with atrial fibrillation (AF). 
 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
We systematically searched the published medical research for 
RCTs comparing new oral anticoagulants to warfarin in patients 
with AF. The Cochrane Library, Embase, MEDLINE, Science 
Citation Index Expanded, and ProQuest's Dissertations and Theses 
databases were searched from inception through July 2011 without 
language restriction. The following were used as Medical Subject 
Heading terms and/or keywords: “new oral anticoagulants,” “oral 
thrombin inhibitors,” “oral factor Xa inhibitors,” “dabigatran,” 
“rivaroxaban,” “apixaban,” “edoxaban,” “betrixaban,” “ym-150,” 
and “LY-517717.” 
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Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 
giving rationale.  
 
Studies were included if (1) they were RCTs, (2) they randomized 
subjects to warfarin or to non–vitamin K antagonist oral 
anticoagulants, (3) they were conducted in patients with AF, and 
(4) they were published in peer-reviewed journals. Studies 
examining ximelagatran were excluded because it has since been 
removed from the market because of hepatotoxicity.
6
 Conference 
abstracts and presentations were also excluded, because their 
results may not be final, and such publications undergo more 
limited peer review. Open-label and blinded studies were included, 
because warfarin's need for monitoring makes blinding difficult. 
Finally, to assess the long-term efficacy and safety of these agents, 
only RCTs with follow-up durations of >1 year were included. 
Data extracted from each RCT included patient- and study-level 
characteristics as well as outcomes. Extracted patient- and study-
level characteristics included average age, median follow-up times, 
discontinuation rates, mean CHADS2 scores,
7 gender distribution, 
mean time in the therapeutic range of warfarin, and proportion of 
patients with relevant co-morbidities present at baseline. The main 
efficacy outcome of interest was a composite end point of stroke 
(including hemorrhagic stroke) and systemic embolism. Other 
efficacy outcomes were ischemic and unidentified stroke, 
hemorrhagic stroke, all-cause mortality, vascular mortality, and 
myocardial infarction. The main safety outcome of interest was 
major bleeding. Other safety outcomes were gastrointestinal 
bleeding and intracranial bleeding. 
 
Information 
sources  
7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
We systematically searched the published medical research for 
RCTs comparing new oral anticoagulants to warfarin in patients 
with AF. The Cochrane Library, Embase, MEDLINE, Science 
Citation Index Expanded, and ProQuest's Dissertations and Theses 
databases were searched from inception through July 2011 without 
language restriction. The following were used as Medical Subject 
Heading terms and/or keywords: “new oral anticoagulants,” “oral 
thrombin inhibitors,” “oral factor Xa inhibitors,” “dabigatran,” 
“rivaroxaban,” “apixaban,” “edoxaban,” “betrixaban,” “ym-150,” 
and “LY-517717.” We did not restrict our search to studies 
conducted in patients with AF, to avoid excluding trials that 
reported subgroup data on patients with AF. The Embase and 
MEDLINE searches were limited to clinical trials, and the Embase 
search was further limited to studies performed in humans. The 
Science Citation Index Expanded and ProQuest searches were 
limited to full-text reports. Clinical trial databases, relevant 
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reviews, and the reference lists of retrieved reports were hand 
searched for potentially relevant studies not identified in our 
electronic database search. 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
 
The following were used as Medical Subject Heading terms and/or 
keywords: “new oral anticoagulants,” “oral thrombin inhibitors,” 
“oral factor Xa inhibitors,” “dabigatran,” “rivaroxaban,” 
“apixaban,” “edoxaban,” “betrixaban,” “ym-150,” and “LY-
517717.” 
 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
Studies were included if (1) they were RCTs, (2) they randomized 
subjects to warfarin or to non–vitamin K antagonist oral 
anticoagulants, (3) they were conducted in patients with AF, and 
(4) they were published in peer-reviewed journals. Studies 
examining ximelagatran were excluded because it has since been 
removed from the market because of hepatotoxicity.6 Conference 
abstracts and presentations were also excluded, because their 
results may not be final, and such publications undergo more 
limited peer review. Open-label and blinded studies were included, 
because warfarin's need for monitoring makes blinding difficult. 
Finally, to assess the long-term efficacy and safety of these agents, 
only RCTs with follow-up durations of >1 year were included. 
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Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
Two reviewers independently extracted data from the RCTs. 
Disagreements were resolved by consensus or, if necessary, by a 
third party. Data extracted from each RCT included patient- and 
study-level characteristics as well as outcomes. Extracted patient- 
and study-level characteristics included average age, median 
follow-up times, discontinuation rates, mean CHADS2 scores,
7 
gender distribution, mean time in the therapeutic range of warfarin, 
and proportion of patients with relevant co-morbidities present at 
baseline. The main efficacy outcome of interest was a composite 
end point of stroke (including hemorrhagic stroke) and systemic 
embolism. Other efficacy outcomes were ischemic and unidentified 
stroke, hemorrhagic stroke, all-cause mortality, vascular mortality, 
and myocardial infarction. The main safety outcome of interest was 
major bleeding. Other safety outcomes were gastrointestinal 
bleeding and intracranial bleeding. 
 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
The following were used as Medical Subject Heading terms and/or 
keywords: “new oral anticoagulants,” “oral thrombin inhibitors,” 
“oral factor Xa inhibitors,” “dabigatran,” “rivaroxaban,” 
“apixaban,” “edoxaban,” “betrixaban,” “ym-150,” and “LY-
517717.” We did not restrict our search to studies conducted in 
patients with AF, to avoid excluding trials that reported subgroup 
data on patients with AF. 
 
 
 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this was 
done at the study or outcome level), and how this information 
is to be used in any data synthesis.  
 
Quality assessment of included trials was conducted using the 
Cochrane Collaboration's tool for assessing risk for bias.8 This 
assessment tool evaluates bias in an RCT within the following 
domains: sequence generation; allocation concealment; blinding of 
participants, personnel, and outcome assessors; incomplete 
outcome data; selective outcome reporting; and other potential 
threats to validity. The risk for bias in each domain was classified 
as high, low, or unclear for each RCT. 
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Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
We estimated pooled relative risks (RRs) and corresponding 95% 
confidence intervals (CIs) using DerSimonian and Laird random-
effects models, which account for within- and between-study 
variability. The presence of between-study variability was assessed 
using the Q statistic (with p <0.10 considered significant), and the 
proportion of heterogeneity due to between-study variability was 
estimated using the I2 index. All analyses were conducted using 
Stata version 11.0 (StataCorp LP, College Station, Texas). 
 
Synthesis of 
results  
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
The presence of between-study variability was assessed using the 
Q statistic (with p <0.10 considered significant), and the proportion 
of heterogeneity due to between-study variability was estimated 
using the I2 index. All analyses were conducted using Stata version 
11.0 (StataCorp LP, College Station, Texas). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
 
 
RESULTS   
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Study selection  17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
Our electronic search identified a total of 3,167 reports (Figure 1). 
After removing duplicates, we screened titles and abstracts, and the 
full text of 44 publications was retrieved and evaluated for 
eligibility. Three trials that met our inclusion criteria were 
identified and included in the present study. One trial was 
published as an original report3 with a follow-up report providing 
additional data.9 The other 2 trials were presented as 
ClinicalTrials.gov entries and were subsequently published in peer-
reviewed journals.2, 4 No additional studies were identified from 
Cochrane systematic reviews, manual searches of the reference 
lists of retrieved reports, relevant reviews, or clinical trial 
databases. 
 
 
 
 
 
 
 
 
 
 
 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
In ARISTOTLE, 18,201 patients with nonvalvular AF were 
randomized to either apixaban 5 mg twice daily or to warfarin.2 In 
RE-LY, 18,113 patients with nonvalvular AF were randomized to 1 
of 3 treatment arms: dabigatran 110 mg twice daily, dabigatran 150 
mg twice daily, or warfarin.3, 9 The 150-mg dose was used in our 
analysis because it is the dose administered to patients with AF. 
ROCKET AF compared a 20 mg/day dose of rivaroxaban to 
warfarin in 14,264 patients with nonvalvular AF.4 
These 3 trials randomized a total of 44,563 patients, 22,327 to new 
oral anticoagulants and 22,236 to warfarin. The mean length of 
follow-up ranged from 657 to 730 days, and the average age ranged 
from 70 to 73 years. Mean CHADS2 scores were between 2.1 and 
3.5. Women constituted 35% to 40% of the study populations, and 
the mean time in the therapeutic range of warfarin ranged from 
55% to 64%. 
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Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment (see item 12).  
Quality assessment of included trials was conducted using the 
Cochrane tool for assessing risk for bias. In RE-LY, patients were 
unblinded with respect to dabigatran or warfarin assignment.3, 10 
However, all investigators, coordinating center members, the 
steering committee, the event adjudication committee, and the 
sponsor were blinded during event ascertainment and analyses. As 
such, the risk for bias for RE-LY was described as low for the 
domain of blinding. 
 
 
 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally 
with a forest plot.  
When data were pooled across RCTs, patients randomized to new 
oral anticoagulants had a 22% RR reduction for the composite end 
point of stroke and systemic embolism compared to those 
randomized to warfarin (RR 0.78, 95% CI 0.67 to 0.92; Figure 2). 
The risks for ischemic and unidentified stroke (RR 0.87, 95% CI 
0.77 to 0.99), hemorrhagic stroke (RR 0.45, 95% CI 0.31 to 0.68; 
Figure 2), and all-cause mortality (RR 0.88, 95% CI 0.82 to 0.95; 
Supplemental Figure 1) were also lower in patients randomized to 
new oral anticoagulants compared to patients randomized to 
warfarin. The risk for vascular mortality, using data from the RE-
LY and ROCKET AF trials, was significantly reduced among 
those randomized to new oral anticoagulants (RR 0.87, 95% CI 
0.77 to 0.98; Supplemental Figure 1); ARISTOTLE was excluded 
from this analysis because only event rates, rather than count data, 
were reported. Risk for myocardial infarction was similar between 
new oral anticoagulants and warfarin (RR 0.96, 95% CI 0.73 to 
1.26; Supplemental Figure 2).Safety outcome analyses included 
major bleeding, gastrointestinal bleeding, and intracranial bleeding 
(Figure 3). Analyses of the risks of major bleeding (RR 0.88, 95% 
CI 0.71 to 1.09) and gastrointestinal bleeding events (RR 1.25, 
95% CI 0.91 to 1.72) were inconclusive because of wide 95% CIs. 
However, randomization to a new oral anticoagulant was 
associated with a significant reduction in the risk for intracranial 
bleeding (RR 0.49, 95% CI 0.36 to 0.66). 
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Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
 
When data were pooled across RCTs, patients randomized to new 
oral anticoagulants had a 22% RR reduction for the composite end 
point of stroke and systemic embolism compared to those 
randomized to warfarin (RR 0.78, 95% CI 0.67 to 0.92; Figure 2). 
The risks for ischemic and unidentified stroke (RR 0.87, 95% CI 
0.77 to 0.99), hemorrhagic stroke (RR 0.45, 95% CI 0.31 to 0.68; 
Figure 2), and all-cause mortality (RR 0.88, 95% CI 0.82 to 0.95; 
Supplemental Figure 1) were also lower in patients randomized to 
new oral anticoagulants compared to patients randomized to 
warfarin. The risk for vascular mortality, using data from the RE-
LY and ROCKET AF trials, was significantly reduced among 
those randomized to new oral anticoagulants (RR 0.87, 95% CI 
0.77 to 0.98; Supplemental Figure 1); ARISTOTLE was excluded 
from this analysis because only event rates, rather than count data, 
were reported. Risk for myocardial infarction was similar between 
new oral anticoagulants and warfarin (RR 0.96, 95% CI 0.73 to 
1.26; Supplemental Figure 2).Safety outcome analyses included 
major bleeding, gastrointestinal bleeding, and intracranial bleeding 
(Figure 3). Analyses of the risks of major bleeding (RR 0.88, 95% 
CI 0.71 to 1.09) and gastrointestinal bleeding events (RR 1.25, 
95% CI 0.91 to 1.72) were inconclusive because of wide 95% CIs. 
However, randomization to a new oral anticoagulant was 
associated with a significant reduction in the risk for intracranial 
bleeding (RR 0.49, 95% CI 0.36 to 0.66). 
 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
Quality assessment of included trials was conducted using the 
Cochrane tool for assessing risk for bias. In RE-LY, patients were 
unblinded with respect to dabigatran or warfarin assignment.3, 10 
However, all investigators, coordinating center members, the 
steering committee, the event adjudication committee, and the 
sponsor were blinded during event ascertainment and analyses. As 
such, the risk for bias for RE-LY was described as low for the 
domain of blinding. 
ROCKET AF, a trial whose primary objective was one of 
noninferiority, performed its efficacy and safety analyses on the 
basis of per protocol and as-treated populations rather than the 
intention-to-treat population.4 Although such analyses are 
appropriate for noninferiority designs, they disturb the integrity of 
randomization, leading to potential confounding and selection bias. 
Although an intention-to-treat analysis was provided for the 
primary efficacy outcome of combined stroke and systemic 
embolism, it was not provided for other efficacy and safety 
outcomes.4 Consequently, ROCKET AF was considered unclear in 
the domain of other sources of bias. Importantly, the as-treated 
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population excluded only 28 of 14,264 patients included in the 
intention-to-treat analyses. 
ARISTOTLE, another noninferiority trial, used an intention-to-
treat analysis for all efficacy outcomes but not for safety outcomes, 
for which only patients who received ≥1 dose of study drug were 
considered.2 It was therefore considered unclear in the domain of 
other sources of bias. These safety analyses excluded 61 of 18,201 
patients included in the intention-to-treat population. 
 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
 
 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy 
makers).  
 
 
In our meta-analysis, we found that the new oral anticoagulants 
reduced the risk for a composite end point of stroke and systemic 
embolism compared to warfarin. New oral anticoagulants were also 
found to be associated with a lower risk for key secondary efficacy 
outcomes, including ischemic and unidentified stroke, hemorrhagic 
stroke, all-cause mortality, and vascular mortality, compared to 
warfarin. Our meta-analysis was inconclusive with respect to major 
bleeding and gastrointestinal bleeding but found a substantial 
decrease in the risk for intracranial bleeding. Overall, our results 
support the use of the new oral anticoagulants as alternatives to 
warfarin for long-term anticoagulation therapy in patients with AF. 
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
Our study had 3 potential limitations. First, there was heterogeneity 
among the included trials. They examined different oral 
anticoagulants, and some of the between-trial differences may be 
due to the use of different agents. There was also some 
heterogeneity with respect to the study designs and included 
populations. Therefore, we used random-effects models that 
account for between-study heterogeneity. Second, patients in 
clinical trials are often at lower overall risk for adverse events than 
patients seen in everyday clinical practice.27 Although this may 
affect the generalizability of our results, it likely did not result in 
bias. Third, patients taking warfarin in the included studies were 
more likely to be within its therapeutic range than in real practice. 
One study found that patients in studies monitored by community 
physicians spent 12.2% less time in the therapeutic range compared 
to patients in randomized trials.12 Similar variability is unlikely to 
apply to the same extent to the new oral anticoagulants, because of 
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their fixed dosing and more predictable pharmacokinetic and 
pharmacodynamic properties. The safety and efficacy profiles of 
the new agents relative to that of warfarin may therefore be 
augmented when used outside the controlled clinical trial setting. 
 
Conclusions  26 Provide a general interpretation of the results in the context 
of other evidence, and implications for future research.  
In our meta-analysis, we found that the new oral anticoagulants 
reduced the risk for a composite end point of stroke and systemic 
embolism compared to warfarin. New oral anticoagulants were also 
found to be associated with a lower risk for key secondary efficacy 
outcomes, including ischemic and unidentified stroke, hemorrhagic 
stroke, all-cause mortality, and vascular mortality, compared to 
warfarin. Our meta-analysis was inconclusive with respect to major 
bleeding and gastrointestinal bleeding but found a substantial 
decrease in the risk for intracranial bleeding. Overall, our results 
support the use of the new oral anticoagulants as alternatives to 
warfarin for long-term anticoagulation therapy in patients with AF. 
 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
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Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
A meta-analysis of phase III randomized controlled trials with new 
oral anticoagulants in atrial fibrillation: Comparisons between 
direct thrombin inhibitors vs. factor Xa inhibitors and different 
dosing regimens 
 
 
 
1253 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
Aims: 
Previous studies evaluating the ability of novel oral anticoagulants 
(NOAC) to prevent thromboembolism in  
patients with non-valvular atrial fibrillation (AF) have identified 
differences between the efficacy and safety of the drugs tested. 
Whether these differences reflect differences in direct thrombin or 
Xa inhibition, different dosing regimens or specific aspects of each 
agent or trial has not yet been explored.  
Methods: 
A search was performed on MEDLINE, EMBASE and 
COCHRANE, and ongoing studies were tracked on  
clinicaltrials.gov. Phase III randomized controlled trials of direct 
thrombin inhibitors (DTI) and factor Xa inhibitors (FXaI) vs. 
warfarin in patients with AF were eligible. Data were pooled using 
random-effects, according to the Mantel-Haenszel model. 
Sensitivity analyses were performed on DTI, FXaI, once-daily and 
twice-daily regimens.  
Results: 
Seven studies were pooled, including a total of 80,290 patients. 
Both DTI and FXaI outperformed warfarin  
regarding stroke or systemic embolism, intracranial bl 
eeding, total and cardiovascular mortality. No signifi 
cant differences were found between DTI and FXaI or between 
once-daily and twice-daily regimens. Some drugs performed worse 
than warfarin regarding some secondary endpoints, including: 
edoxaban 30 mg bid on ischaemic stroke, dabigatran on acute 
myocardial infarction, dabigatran 150 mg bid and rivaroxaban 
20mgod on gastrointestinal bleeding.  
Conclusion: 
Our pooled data do not support the hypothesis of a signi 
ficant class-effect of DTI or FXaI, nor the benefit  
of once-daily vs. twice-daily dosing in the setting of AF, 
reinforcing that the choice of NOAC should be adapted to the 
specific patient and focused on the agent itself, rather than the 
pharmacological class or dosing regimen.  
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INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
 
Patients with atrial fibrillation (AF) have an increased risk of death 
[1] and stroke [2]. So far, vitamin-K antagonists (VKA) have been 
the mainstay in the prevention of thromboembolism in patients 
with AF  
[3]. However, the use of these anticoagulants is often challenging 
due to inter and intra-individual variability in dosing, need of 
frequent monitoring and interaction with other drugs or food, and 
this has led to the  
development of other pharmacological alternatives  
[4]. In recent years, several new non-VKA oral anticoagulants 
(NOAC), belonging to one of two different classes (direct thrombin 
inhibitors [DTI] and direct factor Xa inhibitors [FXaI]), have been 
evaluated in patients with non-valvular AF [5].  
1253 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
In the phase III randomized controlled trials, differences regarding 
effi 
cacy and safety have been observed between some of these drugs 
in comparison with warfarin. Whether  
these differences reflect a DTI or FXaI class-effect, different drug 
pharmacokinetics or dosing regimens or relate to specific aspects 
of each agent or trial has never been explored. A meta-analysis 
including data from all phase III randomized controlled trials 
provides the best opportunity to test the existence of differences 
between DTI and FXaI drugs and once and twice-daily agents, 
since head-to-head randomized controlled trials are not likely to be 
performed. Indirect drug comparisons between trials may be 
obtained, thus  
providing a possible way of filling this knowledge gap.  
 
 
1253 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
We performed a search in the databases MEDLINE, EMBASE and 
COCHRANE (from inception to November 21, 2013) using the 
following search string:  
“atrial  fibrillation  AND  warfarin  AND (apixaban  OR 
Dabigatran  OR  edoxaban  OR  rivaroxaban  OR  ximelagatran)”.  
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Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 
giving rationale.  
 
All phase III randomized controlled trials investigating NOAC 
versus warfarin in patients withnon-valvular AF were considered 
for inclusion. Despite being left out of most previous pooled 
NOAC analyses, trials involving ximelagatran provide an 
important opportunity of accessing DTI behaviour, since this is the 
only agent of this class besides dabigatran to be tested in patients 
with AF. Therefore, all trials of NOAC were included irrespective 
of commercial availability of the study drug. Assessment of 
efficacy and safety endpoints during follow-up was mandatory. 
Substudies of randomized controlledtrials,phase II randomized 
con- 
trolled trials, observational real-world experience with NOAC and 
controlled trials in the setting of interventions (e.g. catheter 
ablation of AF) were not eligible for analysis. The population, 
intervention, comparison and outcome (PICO) approach was used 
for conducting the meta-analysis[6]. The population of interest 
included patients with non-valvular AF, and the intervention was 
oral anticoagulation. Comparisons were performed between the 
following groups: warfarin versus NOAC; DTI versus warfarin; 
FXaI versus warfarin; DTI versus FXaI; once-daily NOAC vs. 
warfarin; twice-daily NOAC vs. warfarin, and once vs. twice-daily 
NOAC. The outcomes were: stroke or systemic embolic events, 
total mortality, cardiovascular mortality, ischaemic stroke, acute 
myocardial infarction, major bleeding, intracranial bleeding and 
gastrointestinal bleeding.  
 
 
 
1254 
Information 
sources  
7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
We performed a search in the databases MEDLINE, EMBASE and 
COCHRANE (from inception to November 21, 2013) using  the 
following  search  string: “atrial  fibrillation  AND  warfarin  AND 
(apixaban  OR dabigatran  OR  edoxaban  OR  rivaroxaban OR  
ximelagatran)”. Reference  lists of all  accessed  full-text articles  
were further searched  for sources of potentially relevant 
information. Ongoing  studies on other  NOAC in non-valvular  AF 
were searched  on  ClinicalTrials.gov, and  experts  in the field 
were contacted to ensure that all important  studies  had  been 
included. Authors of full-text papers and congress abstract authors 
were also contacted  by email  to retrieve additional  information.  
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Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
We performed a search in the databases MEDLINE, EMBASE and 
COCHRANE (from inception to November 21, 2013) using  the 
following  search  string: “atrial  fibrillation  AND  warfarin  AND 
(apixaban  OR dabigatran  OR  edoxaban  OR  rivaroxaban OR  
ximelagatran)”. 
 
 
1254 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
All phase III randomized controlled trials investigating NOAC 
versus warfarin in patients withnon-valvular AF were considered 
for inclusion. Despite being left out of most previous pooled 
NOAC analyses, trials involving ximelagatran provide an 
important opportunity of accessing DTI behaviour, since this is the 
only agent of this class besides dabigatran to be tested in patients 
with AF. Therefore, all trials of NOAC were included irrespective 
of commercial availability of the study drug. Assessment of 
efficacy and safety endpoints during follow-up was mandatory. 
Substudies of randomized controlledtrials,phase II randomized 
con- 
trolled trials, observational real-world experience with NOAC and 
controlled trials in the setting of interventions (e.g. catheter 
ablation of AF) were not eligible for analysis. 
1254 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
To ensure that all trials met the pre-specified inclusion criteria, 
search results were reviewed by two investigators (RP and SBa), 
who needed to reach consensus on study selection; if necessary, a 
third in- 
vestigator (SBo) intervened. Data extraction and presentation for 
the preparation of this manuscript followed the recommendations 
of the PRISMA group 
[7]. Study quality was formally evaluated using the Del- 
phi Consensus criteria [8].  
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Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
The population, intervention, comparison and outcome (PICO) 
approach was used for conducting the meta-analysis [6]. The 
population of interest included patients with non-valvular AF, and 
the intervention  
was oral anticoagulation. Comparisons were performed between 
the following groups: warfarin versus NOAC; DTI versus warfarin; 
FXaI versus warfarin;DTI versus FXaI; once-daily NOAC vs. 
warfarin;twice-daily  
NOAC vs. warfarin, and once vs. twice-daily NOAC. The 
outcomes were:stroke or systemic embolic events, total mortality, 
cardiovascular mortality, ischaemic stroke, acute myocardial 
infarction, major bleeding, in- 
tracranial bleeding and gastrointestinal bleeding.  
 
 
 
1254 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this was 
done at the study or outcome level), and how this information 
is to be used in any data synthesis.  
 
Using funnel plots for evaluation the presence of publication bias 
was not considered appropriate, since less than 10 studies 
(minimum number for assuring the appropriateness of the method) 
were included [11] 
. Heterogeneity-adjusted trial sequential analysis was applied to the 
meta-analysis to reduce the risk of random error due to repetitive 
testing of accumulating data [12].  
 
1254 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
Comparison of the treatment effect of adjusted-dose  
warfarin vs. NOAC was performed using risk ratios (number of 
events or the incidence in each treatment group) and respective 
95% confidence intervals. Pairwise comparisons were performed 
for all assessed  
endpoints. Data were used from the intention-to-treat populations 
unless otherwise specified. 
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Synthesis of 
results  
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
 
Statistical heterogeneity on each outcome of interest was assessed 
and quantified using the Cochran Q test and the I2 statistic, 
respectively. The I2 statistic describes the percentage of total 
variation across studies  
due to heterogeneity rather than chance. Values below 25%, 25% 
to 50% and higher than 50% are, by convention, classified as low, 
moderate, and high degrees of heterogeneity. Using funnel plots for 
evaluation the presence of publication bias was not considered 
appropriate, since less than 10 studies (minimum number for 
assuring the appropriateness  
of the method) were included[11]. Heterogeneity-adjusted trial 
sequential analysis was applied to the meta-analysis to reduce the 
risk of random error due to repetitive testing of accumulating data 
[12].  
The optimal information size with adaptation of monitoring 
boundaries, and the cumulative Z-statistics after each trial were 
assessed (Supplementary material). This was based on an α 
significance level of 5% and  
A β of 20% (80% power), the observed risk reduction, incidence 
rate in the control group and the variation across trials (I2).  
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Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
Using funnel plots for evaluation the presence of publication bias 
was not considered appropriate, since less than 10 studies 
(minimum number for assuring the appropriateness of the method) 
were included. 
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Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
Three sensitivity analysis were performed: the 
first excluding data from the “stroke prevention using oral 
thrombin inhibition in atrial fibrillation”  
(SPORTIF) III and V trials, since the drug was withdrawn from 
development after lack of approval by the Federal Drug Agency as 
a result of hepatotoxicity  
[5]; the second excluded data from “Japanese Rivaroxaban Once 
daily oral direct Factor Xa inhibition Compared with vitamin K 
antagonism for prevention of stroke and Embolism Trial in Atrial 
Fibrillation”  
(J-ROCKET AF) since, according to Japanese 
guidelines, patients above 70 years had a target international 
normalized ratio of 1.6 to 2.6[10], and therefore, different from the 
one used in other trials (2.0 to 3.0). Moreover, a lower dose of 
rivaroxaban  
(15 mg once-daily) was used; the third excluded data from all three 
studies.  
 
 
1254 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
A total of 2,821 entries were retrieved for analysis of titles and 
abstracts. Of these, 2,677 were excluded as they were either 
duplicates or deemed unsuitable for the purpose of our meta-
analysis (editorials, letters, reviews or case-reports). The remaining 
144 results were care- 
fully screened, and after analysis of the full-text (in case of journal 
articles), 7 studies[13–19]were considered adequate for the purpose 
of our meta-analysis. The selection process is illustrated in Fig. 1.  
There was a good agreement between investigators on the inclusion 
of the selected trials. No ongoing phase III NOAC trials in patients 
with AF were found on clinicaltrials.gov.  
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Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
 
Baseline data and the design of selected trials are summarized in 
Tables 1 and 2. 
 
1254 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment (see item 12).  
. 
 
 
 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally 
with a forest plot.  
When analyzing DTI and FXaI together, NOAC were associated 
with a lower incidence of stroke or systemic embolism (RR = 0.84; 
CI 95%0.74-0.95; P = 0.006) and major bleeding (RR = 0.79; CI 
95% 0.67-0.93; P = 0.004) (Fig. 2). Results favouring a better 
outcome with NOAC were also found for total mortality (RR = 
0.90; CI95% 0.86-0.95; Pb 0.0001), cardiovascular mortality (RR = 
0.88; CI 95% 0.83-0.94; P = 0.0002) (Fig. 3) and intracranial 
bleeding (RR = 0.49; CI 95% 0.37-0.63;  
Pb 0.00001) (Fig. 4). However, no significant differences between 
the NOAC and warfarin were found concerning the incidence of 
ischaemic  
stroke (RR = 0.97; CI95% 0.83-1.14; P = 0.74), myocardial 
infarction (RR = 1.01; CI95% 0.83-1.24; P = 0.90) and 
gastrointestinal bleeding (RR = 1.07; CI 95% 0.86-1.34; P = 0.53) 
(Figs. 4 and 5).  
Concerning total mortality and cardiovascular mortality (Fig. 3), a 
significant risk reduction was observed for FXaI when compared 
with warfarin (RR = 0.89; CI 
95% 0.84-0.95; P = 0.0002; I2= 0% and RR = 0.88; CI 
95% 0.81-0.94; P = 0.0006; I2 = 0%, respectively). A non-
significant absolute reduction was observed for both endpoints for 
DTI (RR = 0.92; CI 95% 0.84-1.01; P = 0.07; I2= 0% and RR = 
0.96; CI 95% 0.73-1.25; P = 0.75; I2= 41%, respectively), despite 
the marginally sig- 
Nificant trend for a reductionin the“Randomized Evaluation of 
Long Term Anticoagulant Therapy With Dabigatran Etexilate” 
(RE-LY) trial[15].  
When compared with warfarin, only FXaI reduced the incidence of 
stroke or systemic embolism (FXaI: RR = 0.83; CI 95% 0.72-0.95; 
P = 0.006; I2= 36%; DTI: RR = 0.91; CI 95%0.64-1.28; P = 0.58; 
I2= 68%). The neutral result of DTI is explained by the less 
favourable results of the SPORTIF V trial (Fig. 2).  
DTI were associated with a lower risk of major bleeding when 
compared with warfarin (RR = 0.85; CI 95%  
1254, 
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0.77-0.95; P = 0.003; I2= 0%) and a similar trend was found for 
FXaI, despite the neutral results of the two rivaroxaban trials (RR = 
0.78; CI 95% 0.61-1.01; P = 0.06; I2=90%)(Fig. 2).  
Regarding myocardial infarction and ischaemic stroke, no 
significant differences were found when comparing all DTI or 
FXaI trials with warfarin (Figs. 5). Moreover, a moderate to high 
heterogeneity of study results in each pharmacologic class was 
observed, thus making the existence of specific class effects for 
this event very unlikely. The forest plot of Fig. 4 shows that only 
FXaI were associated with a significant reduction of intracranial 
bleeding (RR = 0.47; CI 95% 0.36-0.62; Pb  
0.00001; I2= 52%). Despite the clear benefit observed with 
dabigatran, pooling of data with ximelagatran displayed a 
numerical but non-significant reduction in this endpoint (RR = 
0.64; CI 95% 0.28-1.48; P = 0.30; I 
2=75%). Regarding gastrointestinal bleeding (Fig. 4), FXaI 
performed similarly to warfarin (RR = 1.00; CI 
95% 0.74-1.36; P = 0.98; I2=81%),despite the results of 
the“Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared with Vitamin K Antagonism for Prevention of Stroke 
and Embolism Trial in Atrial Fibrillation“ (ROCKET-AF) trial, 
whereas DTI  were associated with a significant increase in 
gastrointestinal bleeding (RR = 1.28; CI 95% 1.05-1.56; P = 0.02; 
I2 = 0%), explained by the results of the RE-LY trial.  
 
 
 
 
 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
 
 
 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
 
 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
 
 
In the sensitivity analysis that excluded the SPORTIF III and 
SPORTIF V trials, treatment with DTI (i.e. dabigatran) led to a 
significant reduction in stroke or systemic embolism and 
intracranial bleeding (Table 3). Moreover, a strong trend towards 
an increase in acute myocardial infarction was also uncovered (RR 
= 1.29; CI 95% 0.99-1.69; P = 0.06). In the two scenarios that 
exclude the J-ROCKET AF trial, no changes in the FXaI vs. 
warfarin comparisons were observed.  
1256 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 12:48:21 EET - 137.108.70.7
60 
 
 
 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy 
makers).  
 
Three main conclusions can be drawn from this meta-analysis: 
Firstly, the pooled results confirm the overall benefit of NOAC 
over warfarin for most effi 
cacy and safety endpoints among patients with non- 
valvular AF. Secondly, the observed heterogeneity in results does 
not provide support for a possible class-effect of DTI or FXaI but 
rather suggests that specific properties characterise particular 
agents or trials. Thirdly, no clear benefits were observed in favour 
of any NOAC dosing regimen (once vs. twice-daily).  
 
 
 
1258 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Several limitations are commonly linked to the methodology of 
meta-analyses. Cross-study comparisons deal with some 
drawbacks, as previously discussed (e.g. control groups treated 
with warfarin  
were not identical in TTR, patients population, etc). Moreover, 
trials with DTI provided a much smaller population than FXaI and 
featured only two drugs, which may have impacted on comparisons 
between  
DTI and FXaI. Second, FXaI and DTI, as separate drug classes 
among the NOAC, have been previously assessed in other meta-
analyses of randomized controlled trials [27-29]. However, some 
differences between the present study and previous ones should be 
highlighted. Besides AF [29], these included other clinical settings 
(venous thromboembolism [27] or AF and venous 
thromboembolism [28]). In all three of them  
[27–29], DTI and FXaI were compared with warfarin 
[27–29], placebo [27] or low molecular weight heparin 
[28], whereas no direct comparisons between the two NOAC 
classes were performed. The same applies to comparisons between 
once and twice-daily 
dosing regimens of NOAC in AF[28,29]. Randomized controlled 
trials with edoxaban, the most recent NOAC, were not included in 
any of them. One of these studies included randomized controlled 
trials with ximelagatran and was also the only one to provide data 
on optimal information size assessed through trial sequential 
analysis[29]. Third, due to the limited number of included studies 
the results obtained from methods assessing study heterogeneity 
1263 
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(like the I2) must be  
interpreted with caution. Also, a restricted sample size can be an 
issue when performing of a meta-regression. The Cochrane 
handbook suggests a minimum of 10 studies for using this 
method[11].  
Finally, differences exist in the definition of major bleeding (Table 
VI– Supplementary material).  
 
 
Conclusions  26 Provide a general interpretation of the results in the context 
of other evidence, and implications for future research.  
In patients with AF, NOAC have an overall favourable effect when 
compared with warfarin regarding the risk of stroke or systemic 
embolism, major bleeding, total and cardiovascular mortality and 
intracranial bleeding.  
When restricting the analysis to the two different pharmacologic 
classes, DTI and FXaI, and to different dosing regimens, once-
daily and twice-daily NOAC, a high heterogeneity between studies 
and no pronounced effect in favour of any of these were found. All 
differences and trends in the comparisons could be explained by 
results of isolated trials that were not reproduced by other agents of 
thesame class or with  
the same dosing regimen. Thus, current evidence shows that the 
choice of a NOAC for AF thromboembolic prophylaxis should be 
adapted to the individual patient and focused on the drug itself, 
rather than its pharmacologic class.  
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According to the checklist items that were fullfilled, meta-analysis No1 received 23 
points, meta-analysis No2 received 24 points and meta-analysis No3 received 2 points ( 
although we did not have access to the full text, so the assessment is not complete). Meta-
analysis No4 received 23 points and meta-analysis No5 received 24 points. The results 
are shown at table 1. 
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Table 1: 
 
  
Summary of the results of applying the PRISMA statement to the 
individual meta-analyses 
  
PRISMA statement results 
      
  
       
  
    SCORE   
  
   
   
Meta-
analysis 
No1 
Meta-
analysis 
No2 
Meta-analysis 
No3 
Meta-
analysis 
No4 
Meta-
analysis 
No5 
   
Title 1 Title 1 
 
1 
 
1 
 
1 1 
   
Abstract 2 
Structured 
summary 
1 
 
1 
 
1 
 
1 1 
   
Introduction 3 Rationale 1 
 
1 
 
0 
 
1 1 
   
Methods 4 Objectives 1 
 
1 
   
0 1 
 
5 
Protocol and 
registration 
1 
 
1 
 
0 
 
1 1 
 
6 Eligibility criteria 1 
 
1 
 
0 
 
1 1 
 
7 
Information 
sources 
1 
 
1 
 
0 
 
1 1 
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8 Search 1 
 
1 
 
0 
 
1 1 
 
9 Study selection 1 
 
1 
 
0 
 
1 1 
 
10 
Data collection 
process 
1 
 
1 
 
0 
 
1 1 
 
11 Data items 1 
 
1 
 
0 
 
1 1 
 
12 
Risk of bias in 
individual studies 
1 
 
1 
 
0 
 
1 1 
 
13 
Summary 
measures 
1 
 
1 
 
0 
 
1 1 
 
14 Synthesis of results 1 
 
1 
 
0 
 
1 1 
 
15 
Risk of bias across 
studies 
1 
 
1 
 
0 
 
0 1 
 
16 
Additional 
analyses 
0 
 
1 
 
0 
 
0 1 
   
Results 17 Study selection 1 
 
1 
 
0 
 
1 1 
 
18 
Study 
characteristics 
1 
 
1 
 
0 
 
1 1 
 
19 
Risk of bias within 
studies 
1 
 
1 
 
0 
 
1 0 
 
20 
Results of 
individual studies 
1 
 
0 
 
0 
 
1 1 
 
21 Synthesis of results 1 
 
0 
 
0 
 
1 0 
 
22 
Risk of bias across 
studies 
0 
 
0 
 
0 
 
1 0 
 
23 
Additional 
analyses 
0 
 
1 
 
0 
 
0 1 
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Discussion 24 
Summary of 
evidence 
1 
 
1 
 
0 
 
1 1 
 
25 Limitations 1 
 
1 
 
0 
 
1 1 
 
26 Conclusions 1 
 
1 
 
0 
 
1 1 
   
Funding 27 Funding   0  
  1 
 
 
0  
       1        1 
Total   
 
23 
 
 
24 
 
 
2 
 
       23        24 
 
 
 
 
 
 
CONCLUSION: 
Generally, most of the meta-analyses found received high scores. Title, abstract and 
introduction met the prisma criteria. Synthesis of results, risk of bias across studies and 
additional analyses are the checklist items for which most of the meta-analyses did not 
get a point. This indicates a deficiency of the studies as far as these three checklist items 
are concerned. According to the prisma checklist, meta-analyses No2 and No5 received 
the highest score. Therefore, these meta-analyses are more complete and adequate, 
compared with the other three meta-analyses found. However, the fact that most studies 
received high scores indicates that the meta-analyses of randomized-controlled trials 
exploring the efficacy and safety of the new anticoagulants versus warfarin in patients 
with atrial fibrillation have a good reporting quality. 
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